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The prognosis of immunoglobulin light-chain (AL or pri-mary systemic) and transthyretin (ATTR) amyloidosis is 
substantially influenced by the presence and severity of car-
diac involvement, which then governs therapeutic strategies.1,2 
Although blood biomarkers are useful guides for risk stratifica-
tion,3 they are not specific for cardiac involvement, and current 
strategies do not ascertain all patients at risk. Mortality, despite 
treatment progress, remains high.4–7 Over the last decade, new 
chemotherapy regimens and stem cell transplantation have 
been associated with improved survival in patients with AL 
amyloidosis, but the prognosis remains poor in those with car-
diac involvement, which also contributes substantially to treat-
ment-related morbidity and mortality. There remains a large 
unmet need for improved noninvasive criteria to stratify risk 
in selecting optimal therapy while avoiding serious toxicities.
Editorial see p 1525 
Clinical Perspective on p 1579
Background—The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) 
and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic 
resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but 
its potential for stratifying risk is unknown.
Methods and Results—Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic 
mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects 
were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive inversion recovery (PSIR) and 
without (magnitude only). These were compared with extracellular volume measured with T1 mapping. PSIR was superior 
to magnitude-only inversion recovery LGE because PSIR always nulled the tissue (blood or myocardium) with the longest 
T1 (least gadolinium). LGE was classified into 3 patterns: none, subendocardial, and transmural, which were associated with 
increasing amyloid burden as defined by extracellular volume (P<0.0001), with transitions from none to subendocardial LGE 
at an extracellular volume of 0.40 to 0.43 (AL) and 0.39 to 0.40 (ATTR) and to transmural at 0.48 to 0.55 (AL) and 0.47 to 
0.59 (ATTR). Sixty-seven patients (27%) died. Transmural LGE predicted death (hazard ratio, 5.4; 95% confidence interval, 
2.1–13.7; P<0.0001) and remained independent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, 
stroke volume index, E/E′, and left ventricular mass index (hazard ratio, 4.1; 95% confidence interval, 1.3–13.1; P<0.05).
Conclusions—There is a continuum of cardiac involvement in systemic AL and ATTR amyloidosis. Transmural LGE is 
determined reliably by PSIR and represents advanced cardiac amyloidosis. The PSIR technique provides incremental 
information on outcome even after adjustment for known prognostic factors.  (Circulation. 2015;132:1570-1579. 
DOI: 10.1161/CIRCULATIONAHA.115.016567.)
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Cardiac amyloid deposition represents a key process in 
amyloid pathophysiology.8,9 Cardiovascular magnetic reso-
nance (CMR) with late gadolinium enhancement (LGE) 
identifies myocardial infiltration: after the administration of 
contrast, CMR shows a characteristic pattern of global sub-
endocardial LGE coupled with abnormal myocardial and 
blood-pool gadolinium kinetics.10,11 However, despite excel-
lent diagnostic accuracy for the presence of amyloid, conflict-
ing results have been reported for the prognostic impact on 
AL amyloidosis, and no studies have been published in ATTR 
amyloidosis.12–19 Newer techniques, particularly phase-sensi-
tive inversion recovery (PSIR), an LGE image reconstruction 
technique that is less sensitive to operator choice of null point 
and renders signal intensity truly T1 weighted, may better 
reflect extent of cardiac involvement20 and thereby improve 
risk stratification.
We report here a prospective CMR study conducted in 
amyloidosis in which we investigated the prognostic value of 
LGE in 250 consecutive CMR-eligible subjects. The aims of 
the study were to assess the LGE patterns and the benefit of 
new more robust approaches (PSIR), the correlation with the 
cardiac amyloid burden, and the prognostic impact of LGE in 
both AL and ATTR cardiac amyloidosis.
Methods
Amyloidosis Patients 
Subjects were prospectively recruited at the National Amyloidosis 
Center, Royal Free Hospital, London, UK, from 2010 to 2014 (Figure 
I in the online-only Data Supplement). Outcome (dead/alive) was 
ascertained from death certificates. A total of 250 patients were cat-
egorized into 3 groups. The first group included 119 subjects with 
biopsy-proven systemic AL amyloid (77 male, 65%; age, 62±10 
years), with biopsies from the myocardium (n=7, 6%) or other tis-
sues (n=112, 94%). The second group comprised 122 consecutive, 
consenting patients with ATTR amyloidosis (101 male, 83%; age, 
71±11years). Sixty-nine percent (n=84) had histological proof of 
ATTR amyloidosis by Congo red and immunohistochemical staining 
of myocardial (n=35, 29%) or other (n=49, 40%) tissues. The presence 
of cardiac amyloid was defined by the presence of ATTR amyloid in 
a myocardial biopsy or positive technetium-labeled bone scintigraphy 
using 3,3-diphosphono-1,2-propanodicarboxylicacid (DPD scintigra-
phy). All subjects underwent sequencing of exons 2, 3, and 4 of the 
TTR gene. The third group was made up of 9 subjects with amyloido-
genic TTR gene mutations (3 male, 33%; age, 47±6 years) defined as 
individuals with no evidence of clinical disease (no cardiac uptake on 
DPD scintigraphy and normal echocardiography, CMR, N-terminal 
pro-brain natriuretic peptide [NT-proBNP], and troponin T).
Exclusion Criteria
We excluded all patients with contraindications to CMR: glomerular 
filtration rate <30 mL/min and CMR-incompatible devices. All ethics 
were approved by the University College London/University College 
London Hospital Joint Committees on the Ethics of Human Research 
Committee, and all participants provided written informed consent.
CMR Image Acquisition
All subjects underwent standard CMR on a 1.5-T clinical scanner 
(Avanto, Siemens Healthcare, Erlangen, Germany). Within a standard 
clinical scan (pilots, transverse white- and black-blood images, cines 
images to assess volumes and mass), LGE imaging was acquired with 
magnitude-only inversion recovery (MAG-IR) and PSIR sequence 
reconstructions in 43% of patients.
T1 measurement was performed with the use of the shortened 
modified look-locker inversion recovery sequence (ShMOLLI)21 with 
regions of interest drawn in the 4-chamber view at the level of the 
basal and mid inferoseptum (2 segments, large region of interest).22 
After a bolus of gadoterate meglumine (0.1 mmol/kg, gadolinium-
DOTA, Dotarem, Guerbet S.A. France) and standard LGE imaging 
(standard  fast low-angle shot inversion recovery or balanced steady 
state free precession sequence with MAG-IR and PSIR reconstruc-
tion), the patient was removed from the scanner. The extracellular 
volume (ECV) measurement approach used equilibrium CMR with 
a primed infusion: At 15 minutes after bolus, an infusion at a rate 
of 0.0011 mmol·kg−1·min−1 contrast (equivalent to 0.1 mmol/kg over 
90 minutes) was given. Between 45 and 80 minutes after bolus, the 
patient was returned to the scanner with the infusion continuing, and 
the T1 measurement was repeated using the same parameters of the 
precontrast ShMOLLI sequence.
CMR LGE Interpretation
During interpretation, before our adoption of PSIR for all amyloido-
sis patients, because myocardial nulling can be difficult in the pres-
ence of amyloid, any confusion with MAG-IR images was resolved 
by selecting the images that most matched the postcontrast T1 maps, 
with “bright” LGE expected to correlate with areas with the lowest 
postcontrast T1 (ie, the highest gadolinium concentration, the highest 
interstitial expansion).
The LGE pattern was classified by 2 different observers (M.F. and 
S.P.) into 3 groups according to the degree of transmurality: group 1, 
no LGE; group 2, subendocardial LGE (when there was global sub-
endocardial involvement but no transmural LGE); and group 3, trans-
mural LGE (when the LGE was extending transmurally; Figure 1). 
Thus, a patient with basal transmural LGE but apical subendocardial 
LGE would be classified as transmural LGE.
Figure 1. Characteristic phase-sensitive inversion 
recovery late gadolinium enhancement (LGE) 
patterns in 3 patients with immunoglobulin 
light-chain amyloidosis (AL) and 3 patients with 
transthyretin amyloidosis (ATTR). Left, No LGE; 
middle, subendocardial LGE; right, transmural LGE.
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CMR PSIR Versus MAG-IR
A sample of 100 images (50 PSIR, 50 MAG-IR reconstruction) was 
analyzed for concordance or discordance with the postcontrast T1 
maps that were used as the truth standard (Figure 2). We considered 
that nulled tissue should be the tissue with the least contrast (longest 
T1 on the postcontrast T1 map). This means that a normal subject 
should have nulled myocardium; a high-infiltration amyloid patient 
should have bright myocardium (transmural) and nulled blood, with 
the possibility of intermediate blood and myocardium nulling con-
currently (typically with “bright” endocardium). This is discussed 
further in the figure legends and Discussion.
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics version 
19 (IBM, Somers, NY) and the R programming language (http://
www.r-project.org/). All continuous variables were normally distrib-
uted (Shapiro-Wilk) except for NT-proBNP and troponin T, which 
were therefore ln-transformed for bivariate testing. These are pre-
sented as mean±SD, and nontransformed NT-proBNP is presented as 
median and quartiles 1 through 3. Comparisons between groups were 
performed by 2-way ANOVA with post hoc Bonferroni correction. 
The χ2 test or Fisher exact test was used to compare discrete data as 
appropriate. Correlations between parameters were assessed with the 
Pearson r or Spearman ρ. To assess the agreement of the assignment 
of the LGE pattern by 2 different observers, the intraclass correla-
tion coefficient was calculated. Statistical significance was defined 
as P<0.05.
Survival was evaluated with Cox proportional hazards regres-
sion analysis, providing estimated hazard ratios with 95% confidence 
intervals and Kaplan–Meier curves. Variables selected a priori for 
clinical relevance and first explored with univariate Cox regression 
were entered into the multivariable models. Multivariable mod-
els evaluated the independent predictive value of LGE above other 
clinically and statistically significant covariates. The Harrell C statis-
tic was calculated for the different models.
Results
Study Population
The details of the 250 subjects are shown in Table 1. At the time 
of scanning, the AL amyloidosis cohort had 46 new untreated 
(to date) patients, 21 patients undergoing second- or third-
line therapy, and 52 stable patients (complete or very good 
response, 80%; stable partial response, 20%). UK first-line 
therapy at the time of this study was typically cyclophospha-
mide, thalidomide, and dexamethasone or cyclophosphamide, 
bortezomib, and dexamethasone. Relapse therapy was typi-
cally cyclophosphamide, bortezomib, and dexamethasone or 
a lenalidomide-containing regimen. The TTR mutations were 
as follows: V122I, n=23; T60A, n=13; V30M, n=10; E54G, 
n=2; S77Y, n=2; E89K, n=2; and D38Y, G47V, E89K, I84S, 
I107F, and L12P, n=1 each. Of the 9 asymptomatic individu-
als with TTR mutations, 5 had TTR V30M, 3 had T60A, and 
1 had S77Y.
MAG-IR Versus PSIR
MAG-IR LGE and T1 maps were discordant in 57% (in which 
the operator was selecting the inversion time according to his/
her best judgment), meaning that operator TI selection was 
mainly incorrect. Ten patients with MAG-IR only had no LGE 
images that matched the T1 mapping for classification (imply-
ing that the operator systematically kept the TI incorrect for 
Figure 2. Characteristic cardiovascular magnetic 
resonance scans. Late gadolinium enhancement 
(LGE) with magnitude reconstruction (left); 
LGE with phase-sensitive inversion recovery 
reconstruction (PSIR; middle); and postcontrast 
shortened modified look-locker inversion recovery 
sequence (ShMOLLI) T1 maps (right). On PSIR, 
there is 100% concordance between myocardial T1 
and LGE: first, areas of low T1 (darkest blue) and 
focal areas of LGE; second, where myocardial T1 is 
lower than blood T1, global LGE is demonstrated; 
and third, where myocardial T1 is higher than blood 
T1, no LGE is demonstrated. On magnitude-only 
inversion recovery (MAG) images, discordance 
is present in all 4 of these cases: mid myocardial 
rather than subendocardial (A), apical rather than 
basal (B), transmural LGE rather than normal (C), 
and normal rather than transmural (D).
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the whole scan). All patients with PSIR LGE had diagnostic 
images. PSIR LGE and T1 maps were never (0%) discordant 
(Figures 2 and 3). MAG-IR could be incorrect in 3 ways: 
inappropriately nulling global LGE (Figure 2D), particu-
larly the highest ECV cases; getting the incorrect distribution 
(especially making LGE apical rather than basal; Figure 2A 
Table 1. Main Clinical Characteristics and Echocardiographic and ECG Findings in Patients With AL and ATTR Amyloidosis 
According to the LGE Pattern
All Patients (n=250)
AL Patients* ATTR Patients
No LGE (n=37)
Subendocardial LGE 
(n=42)
Transmural LGE 
(n=30) No LGE (n=17)
Subendocardial LGE 
(n=31)
Transmural LGE 
(n=83)
Age, y 67±12 63±10 61±11 60±12 55±14 74±10 73±9§
Hypertension, % 20 35 12 3‡ 17 35 18
eGFR, 
mL·min−1·1.73 m−2
67±22 72±26 74±19 73±22 80±13 63±21 57±20§
Systolic BP, mm Hg 123±19 138±20 121±19 112±16§ 128±20 133±16 118±15§
Diastolic BP, mm Hg 74±12 81±11 73±11 71±11§ 76±10 77±11 72±11
NT-proBNP, pmol/L 210 (71–446) 29 (9.5–75) 134 (84–370) 319 (186–823)§ 8 (4–12) 196 (89–359) 412 (245–629)§
6 MWT, m 318±135 284±126 301±125 274±148 500±71 328±138 305±120§
PR, ms 188±51 157±25 180±45 186±46† 154±40 188±34 222±58§
QRS, ms 107±26 95±16 101±24 103±19 90±9 114±29 120±29§
Sum limb leads 
voltage, mm
31±15 37±15 30±14 23±16§ 39±11 35±15 28±14†
E wave, cm/s 0.79±0.19 0.67±0.21 0.81±0.20 0.84±0.22‡ 0.73±0.13 0.85±0.18 0.80±0.17
A, cm/s 0.61±0.25 0.78±0.18 0.72±0.23 0.57±0.25‡ 0.65±0.16 0.61±018 0.41±0.20§
E/A 1.59±0.92 0.89±0.33 1.27±0.64 1.80±0.92§ 1.12±0.28 1.52±0.85 2.3±1.05§
Average E′, cm/s 0.06±0.03 0.08±0.02 0.07±0.03 0.06±0.02‡ 0.11±0.04 0.06±0.02 0.05±0.01§
E/E′ 14±7 10±6 13±6 18±9§ 7±3 15±4 17±6§
E-wave deceleration 
time, ms
183±61 212±62 190±51 173±54† 194±73 200±81 162±50†
All continuous variables are presented as mean±SD with nontransformed NT-proBNP presented as median and quartiles 1 through 3. AL indicates light-chain 
amyloidosis; ATTR, transthyretin amyloidosis; BP, blood pressure; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhancement; LV, left ventricular; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; and 6 MWT, 6-minute walking test. 
*Minus 10 patients with nondiagnostic magnitude-only inversion recovery LGE images.
†P<0.05, ‡P<0.01, §P<0.001 for trend (1-way ANOVA) in AL and ATTR patients across different patterns of LGE.
Figure 3. Two patients (top and bottom) with magnitude-only inversion recovery (MAG) and phase-sensitive inversion recovery 
reconstruction (PSIR) late gadolinium enhancement (LGE) reconstruction images (left). In both patients, the MAG and PSIR are discordant 
with opposite LGE patterns. Only one can be correct. The tissue to null is the one with the slowest T1 recovery (ie, the least gadolinium). 
Right, Signal intensity curves as the TI varies for MAG and PSIR. How the operator sets the TI matters in MAG imaging but not in PSIR. 
The operator set the TI for both patients at X, nulling the wrong tissue. The image would have been correct only if the operator had set the 
TI greater than Y. With PSIR, the TI could have been set anywhere, and the tissue with the least gadolinium has lower signal and will be 
nulled after windowing.
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and 2B); or creating transmural LGE where there should be 
global nulling (and the ECV was low; Figure 2C). With PSIR, 
the longest T1 tissue after windowing is always nulled.
LGE Pattern and Correlation With ECV
Three patterns of LGE are observed: no LGE, subendocardial 
LGE, and transmural LGE (Figure 1). There was good agree-
ment in the assignment of these patterns between 2 observ-
ers (intraclass correlation coefficient, 0.97; 95% confidence 
interval, 0.97–098). All patterns were present in AL and 
ATTR cardiac amyloidosis (Figure 1) but to different extents, 
with subendocardial LGE being more prevalent in AL (39% 
in AL versus 24% in ATTR; P<0.05) and transmural LGE 
more prevalent in ATTR (27% in AL versus 63%; P<0.0001; 
Figure 4).
Increasing LGE (none, subendocardial, transmural) was 
associated with increasing ECV (AL: 0.31±0.04, 0.47±0.06, 
and 0.58±0.07; ATTR: 0.29±0.04, 0.50±0.05, and 0.60±0.05; 
P<0.0001 for both; Figure 4). In ATTR, this correlated also 
with DPD grade (P<0.0001). Apparent transitions are evi-
dent, with subendocardial LGE appearing at an ECV of 
0.40 to 0.43 for AL and 0.39 to 0.40 for ATTR and trans-
mural at an ECV of 0.48 to 0.55 for AL and 0.47 to 0.59 
for ATTR. However, 39% of the patients with no LGE had 
ECV elevation compared with normal range (ECV elevation 
between 0.32 and 0.40). Of the patients with no LGE and 
increased ECV, 4 patients had mutant ATTR (and DPD was 
grade 1 in 3 patients and grade 0 in 1 patient), and 17 patients 
had AL amyloidosis.
Increasing LGE (none, subendocardial, transmural) was 
associated in both AL and ATTR with lower systolic blood 
pressure, ECG changes (prolonged PR interval, prolonged 
QRS in ATTR), increased NT-proBNP, structural and func-
tional changes (increased LV mass, increased end-systolic 
volume, decreased stroke volume, decreased ejection fraction, 
left atrial dilatation), increasingly abnormal tissue charac-
terization (elevated native T1 and ECV; Table 2), and more 
severe echocardiographic diastolic dysfunction. In ATTR, 
increasing LGE was also associated with decreased functional 
capacity (6-minute walking test).
LGE Pattern and Prognosis
At follow-up (mean, 24±13 months), 67 of 250 patients (27%) 
had died. Transmural LGE was a significant predictor of mor-
tality in the overall population (hazard ratio, 5.4; 95% confi-
dence interval, 2.1–13.7; P<0.0001; Figure 5).
The survival curves indicates that there is an ≈92% 
chance of survival at 24 months in patients with a no LGE 
Figure 4. Late gadolinium enhancement (LGE) pattern correlation with amyloid burden. Top, Histograms showing the prevalence of the 
different LGE patterns in patients with immunoglobulin light-chain amyloidosis (AL) and patients with transthyretin amyloidosis (ATTR). 
Bottom, Correlation with the amyloid burden measured as extracellular volume (ECV) in AL and ATTR patients. Bonferroni adjustment 
was applied. CI indicates confidence interval.
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(92% in AL, 94% in ATTR) compared with 81% for patients 
with subendocardial LGE (81% in AL, 81% in ATTR) and 
61% with transmural LGE (45% in AL, 65% in ATTR). The 
median survival in patients with transmural LGE was 17 
months in AL and 38 months in ATTR. Transmural LGE was 
significantly associated with mortality (hazard ratio, 4.1; 
95% confidence interval, 1.3–13.1; P<0.05) in multivari-
able Cox models that included NT-proBNP, ejection frac-
tion, stroke volume indexed, E/E′, and left ventricular mass 
indexed (Troponin results were not available in all patients). 
NT-ProBNP and stroke volume indexed also remained inde-
pendently predictive (Table 3). Harrell C statistics for this 
model was 0.72.
The Harrell C statistics of a comparable pre-CMR 
model including demographics, systolic and diastolic 
function parameters, and biomarkers (age, ejection frac-
tion, E/E′, NT-ProBNP, interventricular septal wall thick-
ness) was 0.67.
Discussion
Cardiac infiltration is the chief driver of prognosis in sys-
temic amyloidosis, and stratification of patients is essential 
for prognosis and optimal management, including selection 
of patients to receive aggressive higher-risk therapies and to 
minimize cardiac toxicities. Echocardiography, once the gold 
standard cardiac investigation in amyloidosis, has limited 
sensitivity and specificity, and risk stratification currently 
places great emphasis on blood biomarkers. However, these 
strategies do not identify all amyloidosis patients at risk, 
and the findings of studies evaluating cardiac involvement 
by CMR have been conflicting.4–7,19 Recently, considerable 
interest has emerged in using LGE to improve the risk strati-
fication model,12–19 but studies in AL cardiac amyloidosis 
have been few, mostly small, and retrospective; have used 
nonstandardized LGE approaches; and have produced incon-
sistent results.10,12,13,15,16,19 No studies have been published in 
ATTR amyloidosis.
In the present study, the largest CMR study in amyloidosis 
to date, we showed that misleading results using the MAG-IR 
LGE technique were likely to account for the conflicting 
finding that have previously been published. By convention, 
areas with the most contrast should be displayed as bright on 
LGE imaging (ie, shortest T1 on T1 maps). For amyloidosis, 
myocardium can contain more gadolinium than blood. Under 
those circumstances, myocardium should appear globally 
bright (transmural LGE). It is a property of MAG imaging 
that the signal is highly dependent and nonlinear with a user-
defined choice of the TI (time to null; Figure 2), and images 
can be “inverted” with the wrong TI choice. When all of the 
myocardium is abnormal (seen frequently in cardiac amyloi-
dosis), the abnormal myocardium could be wrongly nulled 
because the MAG-IR relies on “nulling” what is perceived 
to be normal myocardium. This limitation was quantified in 
our study by comparison with a true standard of postcontrast 
Table 2. CMR Findings in Patients With AL and ATTR Amyloidosis According to the LGE Pattern
All Patients (n=250)
AL Patients* ATTR patients
No LGE (n=37)
Subendocardial LGE 
(n=42)
Transmural LGE 
(n=30) No LGE (n=17)
Subendocardial LGE 
(n=31)
Transmural LGE 
(n=83)
LV mass, g 203±77 140±45 170±60 204±56§ 109±25 208±58 266±60§
LV mass
i, g/m
2 108±39 78±29 88±28 108±25§ 61±12 110±26 139±28§
Maximal IVS, mm 15±4 11±2 14±3 16±3 10±2 17±3 19±3†
EDV, mL 125±30 118±29 123±32 114±28 119±25 121±26 138±31‡
EDV
i, mL/m
2 67±16 64±17 65±16 61±16 67±12 64±11 73±16†
ESV, mL 52±27 35±18 42±22 50±21† 38±19 43±21 71±28§
ESV
i, mL/m
2 27±14 18±11 22±12 27±12† 21±9 23±10 38±15§
SV, mL 74±20 83±20 81±21 64±17§ 81±16 78±18 67±18§
SV
i, mL/m
2 39±10 45±9 43±11 35±9§ 46±8 41±9 35±9§
LVEF, % 60±14 72±9 67±12 57±11§ 69±11 65±12 49±13§
LA area, cm2 27±7 23±6 25±6 26±5† 22±3 31±7 32±5§
LA area
i, cm
2/m2 15±3 13±4 13±3 14±2 12±2 16±3 17±1§
RA area,cm2 25±8 21±5 22±6 24±7 20±3 26±8 30±8§
RA area
i,cm
2/m2 13±4 12±3 12±3 13±3 11±2 14±4 16±4§
MAPSE, mm 9±4 12±4 9±4 6±3§ 14±2 9±2 7±2§
TAPSE, mm 15±6 21±3 17±5 12±5§ 23±3 15±5 12±4§
Precontrast T1, ms 1082±75 993±46 1100±58 1150±68§ 968±41 1073±34 1113±47§
ECV, % 0.50±0.12 0.31±0.04 0.47±0.06 0.58±0.07§ 0.29±0.04 0.50±0.05 0.60±0.05§
All variables are presented as mean±SD. AL indicates light-chain amyloidosis; ATTR, transthyretin amyloidosis; CMR, cardiovascular magnetic resonance; ECV, 
extracellular volume; EDV, end-diastolic volume; EDV
i, end-diastolic volume indexed; ESV, end-systolic volume; ESVi, end-systolic volume indexed; IVS interventricular 
septum; LA, left atrial; LA areai, left atrial area indexed; LGE, late gadolinium enhancement; LV, left ventricular; LV massi, left ventricular mass indexed; LVEF, left 
ventricular ejection fraction; MAPSE, mitral annular plane systolic excursion; RA, right atrium; and TAPSE, tricuspid annular plane systolic excursion. 
*Minus 10 patients with nondiagnostic magnitude-only inversion recovery LGE images.
†P<0.05, ‡P<0.01, §P<0.001 for trend (1-way ANOVA) in AL and ATTR patients across different patterns of LGE.
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T1. More important, this problem does not occur with the 
PSIR approach. PSIR substantially removes the issue of 
operator-selected inversion time and completely removes 
the potential for a “mirror image.” On a PSIR reconstruction 
when windowed by the operator, the tissue with the longest 
T1 (least gadolinium, ie, blood or myocardium) after win-
dowing is always nulled. The practical results include the 
following: first, if myocardium is globally nulled by PSIR 
and the ECV is less than blood and <0.4 to 0.43, any amy-
loid present (detectable by an ECV >0.32) is not extensive. 
Second, above this value, LGE areas appear particularly in 
the subendocardium. PSIR LGE areas are the areas of most 
amyloid deposition in the heart. Third, above an ECV of 0.47 
to 0.59, when blood has less gadolinium than myocardium 
and blood is nulled (myocardium appears uniformly bright), 
heterogeneity is present but is swamped by all the myocar-
dium becoming bright. Examples of MAG-IR errors are 
shown in Figure 2: mid myocardial rather than subendocar-
dial (Figure 2A), apical rather than basal (Figure 2B), trans-
mural LGE rather than normal (Figure 2C), and normal rather 
than transmural (Figure 2D).20,23 Accordingly, we believe that 
PSIR should be universally adopted for amyloid LGE imag-
ing, particularly because PSIR-LGE is easily available from 
all scanner manufacturers (whereas T1 mapping is not yet).
With PSIR, 3 patterns were relatively easy to determine, 
and the frequently described LGE pattern of patchy LGE was 
Figure 5. Kaplan–Meier curves for late gadolinium enhancement (LGE) patterns in all patients (top), patients with immunoglobulin light-
chain amyloidosis (AL; bottom left), and patients with transthyretin amyloidosis (ATTR; bottom right).
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not evident with PSIR (many of these on PSIR appeared to 
have transmural LGE). A key insight is that amyloid car-
diac involvement is not dichotomous but a continuum from 
no LGE to subendocardial to transmural tracking increasing 
ECV (Figure 6).24,25 Transmural LGE appears to be the pat-
tern that carries the most adverse prognosis. It is an impor-
tant marker of all-cause mortality after adjustment for other 
relevant disease variables and regardless of treatment status 
(indeed regardless of whether patients are presenting at diag-
nosis or years into the disease process). Indeed, in ATTR, the 
majority of the deaths are in patients with transmural LGE (no 
LGE, subendocardial LGE, and transmural TGE: 1, 6, and 24 
deaths, respectively).
Within this spectrum, the degree of involvement is impor-
tant, with transmural LGE defining the high-risk group. The 
prevalence of patients in the different stages of disease pro-
gression (Figure 6) is different in AL and ATTR. Thirty-nine 
percent of the patients with no LGE had ECVs in the range 
of 0.32 to 0.4, particularly patients with AL amyloidosis. It 
is expected that ATTR patients must pass through this phase, 
but it is not clinically recognized. Early cardiac involvement 
in AL is detected through cardiac screening of AL patients 
presenting with extracardiac disease. The majority of ATTR 
patients (wild-type ATTR and mutant ATTR associated with 
the variant V122I) present with heart failure symptoms that 
appear only when advanced (LGE, mostly transmural, is 
invariably present). This has potential treatment implica-
tions. Currently, patients with subendocardial LGE may be 
classified as having cardiac involvement and denied thera-
pies that are known to improve long-term survival but are 
contraindicated in cardiac involvement such as stem cell 
transplantations (AL), some chemotherapy regimens (AL), 
and liver transplantations (ATTR). More data are needed, 
and consideration of cardiac involvement as a continuum 
should provide insights into the impact of different degrees 
of cardiac infiltration, possibly resulting in changes in the 
current therapeutic approach. Within the transmural pattern, 
the median survival is significantly different in the 2 amyloid 
types: 17 months for AL and 38 months for ATTR. These 
findings support the concept that cardiac amyloid is not a 
disease of solely infiltration but may have superimposed 
toxicity (AL more than ATTR) or that the rate of accumu-
lation is myotoxic, a contributor to different prognoses or 
AL and ATTR despite ATTR having higher degrees of left 
ventricular hypertrophy, cardiac dysfunction, and amyloid 
burden.26 T1 mapping techniques provide new insights into 
this, being able to follow the disease at 3 different levels, that 
is, infiltration (amyloid burden, ECV), edema (native T1), 
and myocyte response (intracellular volume), and providing 
new prognostic markers.27 These new biomarkers may aid 
diagnosis and risk stratifications and act as surrogate end 
points in clinical trials. However, the current limited avail-
ability and the technical challenges related to sequence- and 
vendor-specific differences limit the role of T1 mapping in 
routine clinical practice. The common use of the LGE tech-
nique in all clinical CMR scans and the availability of PSIR 
reconstruction on all different vendor platforms make LGE a 
robust and reliable approach for routine risk stratification of 
patients with cardiac amyloidosis.
Limitations of the study are that patients were at dif-
ferent treatment stages, with treatment reflecting current 
UK practice. Cardiac biopsy was present in only a minor-
ity of patients, but this cohort of patients was fully char-
acterized with all other clinical investigative techniques 
currently available, including DPD scanning. This com-
posite diagnostic pathway is known to provide high 
Table 3. Univariate and Multivariate Analyses of Risk of Death in the Overall Population
Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Transmural LGE 5.38 (2.11–13.72) <0.0001 4.13 (1.30–13.07) <0.05
NT-proBNP, each 100-pmol/L increase 1.03 (1.02–1.05) <0.0001 1.04 (1.02–1.07) <0.0001
SV
i, each 5-mL/m
2 decrease 1.33 (1.19–1.51) <0.0001 1.21 (1.02–1.44) <0.05
LVEF, each 3% 0.91 (0.87–0.96) <0.0001 1.02 (0.94–1.11) 0.634 (NS)
LV mass
i, each 10-g/m
2 increase 1.08 (1.02–1.14) <0.01 0.99 (0.90–1.01) 0.885 (NS)
E/E′, each 1-unit increase 1.07 (1.04–1.10) <0.0001 1.03 (0.99–1.08) 0.145 (NS)
CI indicates confidence interval; HR, hazard ratio; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left 
ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; and SV
i, stroke volume indexed.
Figure 6. Hypothesized cardiac amyloid progression across time. 
When amyloid starts to accumulate, 3 steps can be identified: 
(1) no evidence of late gadolinium enhancement (LGE) but an 
increase in native T1 and extracellular volume (ECV), (2) a further 
increase in T1 and ECV and the appearance of subendocardial 
LGE; and (3) a further increase in native T1 and ECV and 
progression to transmural LGE.
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diagnostic accuracy. The causes of death are not known 
because patients die locally and the National Amyloidosis 
center receives only notification of death, not the cause of 
death. Although this study highlights the prognostic role of 
transmural LGE for risk stratification of patients with car-
diac amyloidosis, further studies are needed to assess the 
direct correlation between patterns of LGE and treatment-
related mortality.
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CLINICAL PERSPECTIVE
Cardiac infiltration is the chief driver of prognosis in systemic amyloidosis. Its assessment aids in the selection of patients 
to receive (or not) aggressive chemotherapy, stem cell therapy, and newer therapies. Currently, stratification uses blood bio-
markers and echocardiography, but echocardiography has limited sensitivity and specificity, particularly in apparently early 
disease and when confounders (such as hypertension) are present. Cardiovascular magnetic resonance shows promise with 
the late gadolinium enhancement (LGE) technique to visualize infiltration, but the technique has always been difficult in 
cardiac amyloidosis because of difficult nulling, with both early and advanced disease being potentially misclassified. Here, 
using T1 mapping as a truth standard (bright myocardium should have the most contrast present), we show in 250 patients 
with both immunoglobulin light chain and transthyretin amyloidosis that a new but widely available LGE technique, phase-
sensitive inversion recovery, completely solves the nulling problems in amyloidosis. With the use of phase-sensitive inver-
sion recovery, the longest T1 tissue after windowing is always nulled. Three LGE patterns are present in cardiac amyloidosis: 
no LGE, subendocardial LGE, and transmural TGE. The transmural LGE pattern is associated with the highest infiltration 
and carries the most adverse prognosis. It is a marker of all-cause mortality, even after adjustment for other relevant disease 
variables. These results suggest that cardiac infiltration is a continuum with the degree of involvement being measurable and 
important, with transmural LGE defining the high-risk group and the subendocardial LGE group being a potential key group 
to focus on for therapy.
